Armstrong preps OTC inhaler IND
This article was originally published in The Tan Sheet
Executive Summary
Generics manufacturer Armstrong Pharmaceuticals expects to file in September an investigational new drug application for an epinephrine inhaler that uses hydrofluoroalkane - a month earlier than expected, according to a presentation prepared by the firm. Roxbury, Mass.-based Armstrong says in the presentation the new formula will better deliver epinephrine than the current Primatene Mist formula, which uses chlorofluorocarbons. An FDA final rule dictates firms remove from the market epinephrine meter-dosed inhalers and other drugs with CFCs or other ozone-depleting substances by the end of 2011 (1"The Tan Sheet" Nov. 24, 2008). Primatene Mist and generic equivalents are the only FDA-approved OTC drug for bronchial asthma. Armstrong aims to launch the new formula, which would comply with the FDA rule, before the 2011 deadline to ensure continued access to an OTC epinephrine MDI, according to the slides. The firm will make the presentation Sept. 25 at an FDA public workshop to discuss alternatives to OTC epinephrine MDIs (2"The Tan Sheet" Aug. 24, 2009)
You may also be interested in...
No Relief In Sight For Future Of OTC Asthma Products
The slated removal of OTC epinephrine inhalers from the market in 28 months raises questions about whether affordable alternatives will be available and whether FDA would approve another nonprescription asthma drug
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.